The fund is an Equity fund and aims to provide investors with long-term capital growth, principally (i.e. at least 70% (and normally 75%) of the fund’s assets) through investment in equity securities of companies throughout the world that are involved in the design, manufacture, or sale of products and services used in health care, medicine or biotechnology.
3 Years Annualised
Fund Size (Mil)
Max Initial Charge
Past performance is not a guide to future performance. Returns may increase or decrease as a result of currency fluctuations. All performance data is calculated NAV to NAV, net of fees, dividends reinvested and does not take account of commissions and costs incurred on the issue and redemption of units. US/Hong Kong dollar-based investors are exposed to currency fluctuations where funds are denominated in currencies other than US/Hong Kong dollars.
Performance data is not available if a share class is less than 12 calendar months old. However performance data for other share classes of the same fund will be available in the factsheet, provided such share classes are more than 12 calendar months old. Performance between share classes may differ due to factors such as hedging strategies and fees.